Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2018
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms OCEAN
- Sponsors Novartis
- 01 Dec 2018 Results published in the Diabetes Therapy
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.